These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 12194173)

  • 1. Registration and reregistration application fees. Confirmation of final rule, remanded for further notice and comment, and response to comments.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2002 Aug; 67(154):51987-52007. PubMed ID: 12194173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Registration and reregistration application fees. Final rule; remanded for further notice and comment.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 1996 Dec; 61(251):68624-6. PubMed ID: 12192680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amendment of the fee exemption for federal, state and local government employees--DEA, Justice. Final rule.
    Fed Regist; 1994 Feb; 59(37):8859. PubMed ID: 10133414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled substances and List I chemical registration and reregistration fees. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2012 Mar; 77(51):15234-50. PubMed ID: 22420065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes to patient limitation for dispensing or prescribing approved narcotic controlled substances for maintenance or detoxification treatment by qualified individual practitioners. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2008 May; 73(100):29685-8. PubMed ID: 18605404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of exemptions for chemical mixtures containing the list I chemicals ephedrine and/or pseudoephedrine. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(133):39611-4. PubMed ID: 18850676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Information on foreign chain of distribution for ephedrine, pseudoephedrine, and phenylpropanolamine. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2010 Mar; 75(43):10168-72. PubMed ID: 20383917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of revisit user fee program for Medicare survey and certification activities. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2007 Sep; 72(181):53627-49. PubMed ID: 17886406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of a chemical precursor used in the illicit manufacture of fentanyl as a List I chemical. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2008 Jul; 73(144):43355-7. PubMed ID: 18949877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of red phosphorus, white phosphorus and hypophosphorous acid (and its salts) as list I chemicals; exclusions and waivers. Final rule.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2003 Jun; 68(121):37411-4. PubMed ID: 12836650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Schedules of controlled substances: rescheduling of buprenorphine from schedule V to schedule III. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2002 Oct; 67(194):62354-70. PubMed ID: 12369590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Issuance of multiple prescriptions for schedule II controlled substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2007 Nov; 72(222):64921-30. PubMed ID: 18038486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Listed chemicals; establishment of non-regulated transactions in anhydrous hydrogen chloride. Final rule confirmation.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 2001 Aug; 66(159):42944-6. PubMed ID: 11757558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescriptions; requirements clarification--Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1991 Jun; 56(106):25025-7. PubMed ID: 10111144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The regulatory process: impacting the NP's role.
    Wysocki S
    Nurse Pract Forum; 1992 Jun; 3(2):56-7. PubMed ID: 1392671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facsimile transmission of prescriptions for patients enrolled in hospice programs. Drug Enforcement Administration (DEA), Justice. Final rule.
    Fed Regist; 2001 Jan; 66(8):2214-5. PubMed ID: 11503757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prescriptions; dispensing controlled substances in institutional practitioner emergency rooms--Drug Enforcement Administration, Justice. Withdrawal of proposed rule.
    Fed Regist; 1983 Jun; 48(125):29713-4. PubMed ID: 10261481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Definition of "positional isomer" as it pertains to the control of schedule I controlled substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2007 Dec; 72(231):67850-2. PubMed ID: 18064769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exemption of chemical mixtures. Final rule.
    Drug Enforcement Administration (DEA), U.S. Department of Justice
    Fed Regist; 2007 Mar; 72(47):10925-8. PubMed ID: 17450656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schedules of controlled substances: placement of alpha-methyltryptamine and 5-methoxy-N,N-diisopropyltryptamine into schedule I of the Controlled Substances Act. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2004 Sep; 69(188):58950-3. PubMed ID: 15455477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.